Great. and year are things of where other things a towards I'd this few end like that happened early have highlight XXXX to either going. the
data is on in fast results, our sumatriptan onset got sumatriptan just first platform. using The preliminary our we the PK showing new ultra on an
in sumatriptan you an and the The on left available on human powder, subcu the you most look the should different delay note but today spray, of the are highlights would thing at between the nasal is the tablet expect. PK We how weren't curves injection. the indication versus graph any of peak injection. this insulin this you as the of The subcu oral market. rep formulations oral data showed is absorption we in formulations These look current tablet PK study, our sure the
peak the XXX note goes versus You concentration a higher to can left. we to see relative here times it on zero two And in just rep on to dosing PK results see that off XXX the XXX first scale first subcu. from the please
this look to As as this we program of explore to we is we onset think migraine, to something forward. continuing progress important speed is forward
at through program resources invest we to out studies. This any or and And reason Usually more wouldn't go we as response, if the preliminary dosing we an can't for us, MannKind and a other spun a our IV-like licensed partner the we Afrezza platform. the this we like of animal. this point, about excited albeit that just ultimately it. on very see is of put products, company. and in for data in partner out We're As we direction go some find indicative toxicity
However, launched has we that that two in to bring data understand I'll new crowded marketplace. value us see and that that generics. market. this prudent is unique say just highlight age, in so I And a think believe Allergan people sumatriptan and a will recently partner it's a can the that get Lilly the certain sumatriptan will to many
look we in lot a as still chronic migraine space forward. happening need there's and So for believe a the acute an We prevention. treatment
six Next, the want to I talk about scientific new presentations.
we to it in world. we almost be $X out, the we continued to see look change in CGM fastest As look took go excited to XX about as years insulin as Afrezza standard. very change the zero billion the from to over We're the
the only first in just first written scratching doctors X% are our These U.S. the and write We for X% here every have the targets Afrezza. month, are ever of single who written rapid-acting one. surface. There's prescription only prescriptions have their
as So to of about ways we we and get and XX% to prescribing the represents market new our believe go get how penetrate think patients. safety Afrezza. we depth to billion going pediatric is, and this PK pediatric market a the This in over to is market, continue one X about see to opportunity we're continue for When there. progress we of long to on explore us but allows the rapid-acting $X Phase Number year-over-year. to how have writers
using the overwhelmed BluHale a days. proper time, someone's to of think prescriber two that last that's change As next bullets device sets which offices, with are standards teaching Afrezza, these And reduced ultimately were to BluHale with building training I'm inhalation educator these confidence administrative show burden care and and paperwork we will that confidence year getting these proud about build around say, who reduces and around data in confidence. demonstrated adoption
BluHale health QX. care here that launch be name of our in we will the professional Pro will addition
fixed-dose able as reduction that data showed This we new were last we've were with therapy a as we on a adding simple regardless Levin Additionally, insulin. X.X% to is from Afrezza the the top that background year show long at seen of Philip ADA they on results by study almost of unbelievable mealtime orals very shown titration.
drive As faster the which year in we've type we very to continued into market diabetes of realize it's a progress this energy X adoption to see X type we is crowded refocused want our change helping the one of space reasons Afrezza.
call X. However, here as excursions out well believe pilot type be X was type closed-loop I'll And we glycemic of long-term, bullet hybrid reducing a a we people need the here as last showing [indiscernible] help the to early do done to living treatment. study it during
high-dose thinking use But can you in the explored to low it the hybrid Afrezza within still is you we when of study This got is results optimize how together. – to opportunities and loops. interesting Afrezza think at look really closed used phenomenon and I an see these and forward BluHale in and space. inform type to out data go move new support continue pumps X about the type forward with door we as X excited pediatric to We're continue get
on in key recently earnings best about placing wider to talked we As QX of really is XXXX focused drive adoption our Afrezza. call,
one here to want we is One really focus. of around the type areas the go
this advocacy be about around year publications all to this going generation really data think starting our into and targeting. sales market. efforts, our TXD our focused build relations, our marketing footprint to our you are and So
and On in specialty starting a patient text in tactics to we that new January fulfillment e-mails compliance. around increase persistency side, pharmacy help reimbursement the right and support network launched with will
up customers out On end We will country. sales how That pilot. patient training of it as finally, around device Pro training possible. the did patient which quickly as of be bottom this March continues well. launch We'll reps to get the a is BluHale this the across really at go And we on training. our and as to to go left scale
of next breadth I'll try of in for Afrezza. and one, The XX buckets. you only break the growth increase months and Afrezza's the sales prescribing. thing to we best Number over stopping prescribing out to expect this What continued four and has force
to trial We the and and a milestone standard long exists a coming of the X we're a Phase it's the a this XXX expect the and for we're to we ready pediatric in here from X,XXX on grow initiate very start will pass going confident think deep that week. change to here. opportunity we to before as TRxs assessment opportunity dive care years. that complete hit time large next the It's to continue been We're landscape
on compounds cystic the can side pipeline website will the pipeline Those we DNA lung well as On fibrosis orphan right, you with as two in in see our disease. tobramycin. as progress alpha
in partnerships Technosphere opportunities of with new initiate outside continue in and to things we the to platform, molecules already. plan We we explore the MannKind marketplace use as other to our device listed
just We readout had in. animal PK in the sumatriptan tadalafil came and
that We but have share an upcoming not seen yet, call. we'll it at
non-strategic out marketplace of these We if and each terminate assets – the spin will can't We we its solve in the a unique the pipeline need. them, of assets believe partner. – them or unmet there's find we'll four serves
resources MannKind. fixed not leveraging continue the the or infrastructure can't the dedicate of have within getting really Phase which build we However, are we X to infrastructure already expensive costs beyond and them that very
to around large again Therapeutics a Treprostinil excited and population XX,XXX to the expands were X, patients Group our very on at get forms United This going which this happy you for and at WHO today. with I'll opportunity United positive all interstitial are outcome get with that partners Current alliance Therapeutics remind XXXX. Tyvaso and expansion is this of we're FDA. disease patients with Our lung filed they
as QX – TreT. track we with continue respectively program trials We're months. expected QX XX-unit achieve that almost XX excited file to $XX-unit in milestone going very complete brief will million clinical – each our next we that complete We and milestone are quarter. It's the to [ph]. to our on within forward And and complete XX% and
funding around sources. is get we questions the of One
do a cash generally look at as our quarter-over-quarter. well about very you than don't reduce showed current QX to is debt little We milestones and as to continue funding but when need QX our burn the a burn will feel we anticipate continue tranches. Steve reduce hand sources higher on you to have as bit raise. Therapeutics good cash cash We United equity our an enough mid-cap
and the to political look very we world the watch at point, we the around remain excited. continue to threat coronavirus. at We But the currently environment this marketplace elections, as
main We have our to faster the balance Afrezza to growing what is we our and cash on need focus do cash manage continuing enough do. to And sheet.
we'll Thank and I stop With that think you. here questions. take
